Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

GENE:

IFNG (Interferon, gamma)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

IFNG gene signature	Melanoma	IFNG gene signature	Melanoma	nivolumab Sensitive: B - Late Trials nivolumab Sensitive : B	nivolumab Sensitive: B - Late Trials nivolumab Sensitive : B
High IFNG gene signature	Melanoma	High IFNG gene signature	Melanoma	atezolizumab + vemurafenib + cobimetinib Sensitive: B - Late Trials atezolizumab + vemurafenib + cobimetinib Sensitive : B	atezolizumab + vemurafenib + cobimetinib Sensitive: B - Late Trials atezolizumab + vemurafenib + cobimetinib Sensitive : B
High IFNG gene signature	Melanoma	High IFNG gene signature	Melanoma	nivolumab Sensitive: B - Late Trials nivolumab Sensitive : B	nivolumab Sensitive: B - Late Trials nivolumab Sensitive : B
IFNG-L	Diffuse Large B Cell Lymphoma	IFNG-L	Diffuse Large B Cell Lymphoma	relmacabtagene autoleucel Sensitive: C3 – Early Trials relmacabtagene autoleucel Sensitive : C3	relmacabtagene autoleucel Sensitive: C3 – Early Trials relmacabtagene autoleucel Sensitive : C3
IFNG overexpression	Melanoma	IFNG overexpression	Melanoma	PD1 inhibitor Sensitive: C3 – Early Trials PD1 inhibitor Sensitive : C3	PD1 inhibitor Sensitive: C3 – Early Trials PD1 inhibitor Sensitive : C3
IFNG 4-genes signature	Non Small Cell Lung Cancer	IFNG 4-genes signature	Non Small Cell Lung Cancer	durvalumab Sensitive: C3 – Early Trials durvalumab Sensitive : C3	durvalumab Sensitive: C3 – Early Trials durvalumab Sensitive : C3
IFNG 4-genes signature	Urothelial Cancer	IFNG 4-genes signature	Urothelial Cancer	durvalumab Sensitive: C3 – Early Trials durvalumab Sensitive : C3	durvalumab Sensitive: C3 – Early Trials durvalumab Sensitive : C3
IFNG gene signature	Urothelial Cancer	IFNG gene signature	Urothelial Cancer	durvalumab Sensitive: C3 – Early Trials durvalumab Sensitive : C3	durvalumab Sensitive: C3 – Early Trials durvalumab Sensitive : C3
IFNG gene signature	Bladder Cancer	IFNG gene signature	Bladder Cancer	durvalumab Sensitive: C3 – Early Trials durvalumab Sensitive : C3	durvalumab Sensitive: C3 – Early Trials durvalumab Sensitive : C3
IFNG gene signature	Non Small Cell Lung Cancer	IFNG gene signature	Non Small Cell Lung Cancer	durvalumab Sensitive: C3 – Early Trials durvalumab Sensitive : C3	durvalumab Sensitive: C3 – Early Trials durvalumab Sensitive : C3
IFNG overexpression	Non Small Cell Lung Cancer	IFNG overexpression	Non Small Cell Lung Cancer	nivolumab Sensitive: C3 – Early Trials nivolumab Sensitive : C3	nivolumab Sensitive: C3 – Early Trials nivolumab Sensitive : C3
IFNG gene signature	Squamous Cell Carcinoma of Head and Neck	IFNG gene signature	Squamous Cell Carcinoma of Head and Neck	pembrolizumab Sensitive: C3 – Early Trials pembrolizumab Sensitive : C3	pembrolizumab Sensitive: C3 – Early Trials pembrolizumab Sensitive : C3